Cara Capital Surpluse vs Net Working Capital Analysis

CARA Stock

USD 5.20 0.40 7.14%

Cara Therapeutic financial indicator trend analysis is way more than just evaluating Cara Therapeutic prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cara Therapeutic is a good investment. Please check the relationship between Cara Therapeutic Capital Surpluse and its Net Working Capital accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cara Therapeutic. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For information on how to trade Cara Stock refer to our How to Trade Cara Stock guide.

Capital Surpluse vs Net Working Capital

Capital Surpluse vs Net Working Capital Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cara Therapeutic Capital Surpluse account and Net Working Capital. At this time, the significance of the direction appears to have strong relationship.

The correlation between Cara Therapeutic's Capital Surpluse and Net Working Capital is 0.67. Overlapping area represents the amount of variation of Capital Surpluse that can explain the historical movement of Net Working Capital in the same time period over historical financial statements of Cara Therapeutic, assuming nothing else is changed. The correlation between historical values of Cara Therapeutic's Capital Surpluse and Net Working Capital is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Surpluse of Cara Therapeutic are associated (or correlated) with its Net Working Capital. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Working Capital has no effect on the direction of Capital Surpluse i.e., Cara Therapeutic's Capital Surpluse and Net Working Capital go up and down completely randomly.

Correlation Coefficient

0.67

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Capital Surpluse

Net Working Capital

Most indicators from Cara Therapeutic's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cara Therapeutic current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cara Therapeutic. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For information on how to trade Cara Stock refer to our How to Trade Cara Stock guide.The current year's Selling General Administrative is expected to grow to about 33.4 M, whereas Issuance Of Capital Stock is forecasted to decline to about 955 K.

	2022	2023	2024	2025 (projected)
Total Operating Expenses	122.1M	136.3M	156.7M	164.6M
Cost Of Revenue	7.3M	6.2M	7.1M	6.7M

Total Operating Expenses Cost Of Revenue

Cara Therapeutic fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt
Total Assets		0.14	0.67	0.74	0.96	0.81	0.05	-0.26	-0.69	0.55	0.33	0.82	-0.21	-0.55	0.98	0.5	0.86	0.8	0.94	0.19	0.69	0.79	0.46	0.06	0.98	0.58
Short Long Term Debt Total	0.14		0.78	0.32	-0.05	0.57	0.84	0.22	-0.71	0.81	0.69	-0.14	0.23	-0.75	0.17	0.79	0.44	0.51	0.04	0.97	0.3	0.67	0.86	0.89	0.21	0.59
Other Current Liab	0.67	0.78		0.74	0.5	0.91	0.61	-0.02	-0.94	0.96	0.69	0.33	-0.08	-0.89	0.69	0.92	0.82	0.84	0.57	0.82	0.7	0.96	0.92	0.65	0.72	0.75
Total Current Liabilities	0.74	0.32	0.74		0.57	0.82	0.16	-0.09	-0.69	0.68	0.35	0.5	-0.15	-0.64	0.76	0.6	0.75	0.73	0.69	0.44	0.68	0.71	0.74	0.19	0.77	0.42
Total Stockholder Equity	0.96	-0.05	0.5	0.57		0.67	-0.09	-0.32	-0.53	0.38	0.22	0.85	-0.25	-0.38	0.93	0.34	0.73	0.67	0.93	-0.01	0.59	0.66	0.24	-0.09	0.91	0.46
Other Liab	0.81	0.57	0.91	0.82	0.67		0.5	-0.12	-0.92	0.85	0.61	0.57	-0.21	-0.89	0.79	0.83	0.83	0.84	0.68	0.66	0.76	0.94	0.83	0.53	0.81	0.76
Property Plant And Equipment Net	0.05	0.84	0.61	0.16	-0.09	0.5		0.35	-0.56	0.63	0.49	0.04	0.27	-0.64	-0.01	0.61	0.22	0.29	-0.09	0.8	0.24	0.52	0.67	0.99	0.02	0.54
Net Debt	-0.26	0.22	-0.02	-0.09	-0.32	-0.12	0.35		0.14	-0.04	-0.55	-0.04	0.72	0.2	-0.31	-0.21	-0.3	-0.28	-0.08	0.15	-0.47	-0.14	0.14	0.33	-0.33	-0.23
Retained Earnings	-0.69	-0.71	-0.94	-0.69	-0.53	-0.92	-0.56	0.14		-0.94	-0.73	-0.37	0.25	0.94	-0.7	-0.93	-0.87	-0.91	-0.54	-0.76	-0.76	-0.97	-0.82	-0.6	-0.74	-0.88
Accounts Payable	0.55	0.81	0.96	0.68	0.38	0.85	0.63	-0.04	-0.94		0.74	0.2	-0.17	-0.91	0.57	0.95	0.77	0.81	0.43	0.84	0.7	0.93	0.89	0.68	0.61	0.74
Cash	0.33	0.69	0.69	0.35	0.22	0.61	0.49	-0.55	-0.73	0.74		-0.04	-0.36	-0.81	0.38	0.84	0.6	0.65	0.11	0.72	0.64	0.7	0.63	0.54	0.43	0.7
Non Current Assets Total	0.82	-0.14	0.33	0.5	0.85	0.57	0.04	-0.04	-0.37	0.2	-0.04		0.01	-0.21	0.7	0.1	0.52	0.48	0.75	-0.14	0.41	0.46	0.14	0.0	0.68	0.33
Non Currrent Assets Other	-0.21	0.23	-0.08	-0.15	-0.25	-0.21	0.27	0.72	0.25	-0.17	-0.36	0.01		0.34	-0.24	-0.34	-0.26	-0.28	-0.09	0.09	-0.61	-0.22	0.1	0.26	-0.29	-0.33
Other Assets	-0.55	-0.75	-0.89	-0.64	-0.38	-0.89	-0.64	0.2	0.94	-0.91	-0.81	-0.21	0.34		-0.56	-0.96	-0.74	-0.79	-0.37	-0.83	-0.78	-0.9	-0.84	-0.68	-0.61	-0.84
Cash And Short Term Investments	0.98	0.17	0.69	0.76	0.93	0.79	-0.01	-0.31	-0.7	0.57	0.38	0.7	-0.24	-0.56		0.54	0.89	0.83	0.94	0.24	0.69	0.79	0.49	0.02	1.0	0.57
Net Receivables	0.5	0.79	0.92	0.6	0.34	0.83	0.61	-0.21	-0.93	0.95	0.84	0.1	-0.34	-0.96	0.54		0.74	0.79	0.35	0.85	0.77	0.9	0.84	0.66	0.59	0.8
Common Stock Total Equity	0.86	0.44	0.82	0.75	0.73	0.83	0.22	-0.3	-0.87	0.77	0.6	0.52	-0.26	-0.74	0.89	0.74		0.97	0.73	0.48	0.76	0.9	0.63	0.27	0.91	0.8
Common Stock Shares Outstanding	0.8	0.51	0.84	0.73	0.67	0.84	0.29	-0.28	-0.91	0.81	0.65	0.48	-0.28	-0.79	0.83	0.79	0.97		0.65	0.55	0.8	0.91	0.67	0.34	0.86	0.86
Short Term Investments	0.94	0.04	0.57	0.69	0.93	0.68	-0.09	-0.08	-0.54	0.43	0.11	0.75	-0.09	-0.37	0.94	0.35	0.73	0.65		0.1	0.49	0.67	0.39	-0.08	0.92	0.35
Non Current Liabilities Total	0.19	0.97	0.82	0.44	-0.01	0.66	0.8	0.15	-0.76	0.84	0.72	-0.14	0.09	-0.83	0.24	0.85	0.48	0.55	0.1		0.4	0.71	0.92	0.85	0.28	0.62
Other Current Assets	0.69	0.3	0.7	0.68	0.59	0.76	0.24	-0.47	-0.76	0.7	0.64	0.41	-0.61	-0.78	0.69	0.77	0.76	0.8	0.49	0.4		0.75	0.52	0.26	0.74	0.72
Other Stockholder Equity	0.79	0.67	0.96	0.71	0.66	0.94	0.52	-0.14	-0.97	0.93	0.7	0.46	-0.22	-0.9	0.79	0.9	0.9	0.91	0.67	0.71	0.75		0.81	0.55	0.82	0.84
Total Liab	0.46	0.86	0.92	0.74	0.24	0.83	0.67	0.14	-0.82	0.89	0.63	0.14	0.1	-0.84	0.49	0.84	0.63	0.67	0.39	0.92	0.52	0.81		0.72	0.52	0.57
Property Plant And Equipment Gross	0.06	0.89	0.65	0.19	-0.09	0.53	0.99	0.33	-0.6	0.68	0.54	0.0	0.26	-0.68	0.02	0.66	0.27	0.34	-0.08	0.85	0.26	0.55	0.72		0.05	0.56
Total Current Assets	0.98	0.21	0.72	0.77	0.91	0.81	0.02	-0.33	-0.74	0.61	0.43	0.68	-0.29	-0.61	1.0	0.59	0.91	0.86	0.92	0.28	0.74	0.82	0.52	0.05		0.61
Short Term Debt	0.58	0.59	0.75	0.42	0.46	0.76	0.54	-0.23	-0.88	0.74	0.7	0.33	-0.33	-0.84	0.57	0.8	0.8	0.86	0.35	0.62	0.72	0.84	0.57	0.56	0.61

Click cells to compare fundamentals

Cara Therapeutic Account Relationship Matchups

Cara Therapeutic fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	271.2M	247.1M	182.2M	125.8M	144.7M	136.4M
Short Long Term Debt Total	5.3M	3.7M	1.9M	43.2M	49.6M	52.1M
Other Current Liab	10.4M	8.5M	10.0M	14.0M	16.1M	16.9M
Total Current Liabilities	18.5M	17.6M	23.5M	25.6M	29.4M	17.5M
Total Stockholder Equity	249.0M	227.5M	158.8M	57.1M	65.6M	112.3M
Property Plant And Equipment Net	5.1M	3.6M	2.0M	8.2M	9.4M	9.9M
Net Debt	(26.4M)	(9.8M)	(61.8M)	(8.6M)	(7.7M)	(8.1M)
Retained Earnings	(392.3M)	(480.8M)	(566.2M)	(684.7M)	(616.3M)	(585.5M)
Accounts Payable	4.9M	5.6M	9.6M	11.6M	13.3M	14.0M
Cash	31.7M	13.5M	63.7M	51.8M	59.5M	62.5M
Non Current Assets Total	76.1M	73.8M	13.3M	9.7M	11.1M	10.6M
Cash And Short Term Investments	180.9M	167.0M	145.4M	100.8M	115.9M	104.8M
Net Receivables	2.1M	1.2M	4.5M	4.0M	4.6M	4.9M
Common Stock Total Equity	39K	47K	50K	53K	61.0K	33.2K
Common Stock Shares Outstanding	47.9M	50.7M	53.7M	54.1M	62.3M	35.8M
Short Term Investments	149.2M	153.6M	81.7M	49.0M	56.3M	93.8M
Liabilities And Stockholders Equity	271.2M	247.1M	182.2M	125.8M	144.7M	136.4M
Non Current Liabilities Total	3.7M	1.9M	11.5M	43.2M	49.6M	52.1M
Other Current Assets	12.1M	2.5M	16.7M	8.6M	9.8M	5.3M
Other Stockholder Equity	641.2M	708.6M	726.6M	742.0M	853.3M	896.0M
Total Liab	22.2M	19.5M	23.5M	68.8M	79.1M	83.0M
Property Plant And Equipment Gross	5.1M	3.6M	2.0M	9.9M	11.3M	11.9M
Total Current Assets	195.1M	173.3M	168.9M	116.2M	133.6M	112.2M
Accumulated Other Comprehensive Income	73K	(358K)	(1.7M)	(260K)	(299K)	(314.0K)
Common Stock	47K	50K	53K	54K	62.1K	35.2K
Property Plant Equipment	700K	840K	631K	426K	383.4K	364.2K
Inventory	(1.5M)	2.6M	2.4M	2.8M	3.2M	3.4M
Net Tangible Assets	190.1M	252.7M	229.4M	158.8M	182.6M	155.7M
Retained Earnings Total Equity	(400.7M)	(392.3M)	(480.8M)	(566.2M)	(509.6M)	(484.1M)
Capital Surpluse	587.2M	641.2M	708.6M	726.6M	835.6M	525.5M
Net Invested Capital	249.0M	227.5M	158.8M	57.1M	65.6M	62.4M
Net Working Capital	176.6M	155.7M	145.5M	90.6M	104.2M	142.3M
Capital Stock	47K	50K	53K	54K	62.1K	54.3K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

CSX	CSX Corporation
ETON	Eton Pharmaceuticals
ALLT	Allot Communications

When determining whether Cara Therapeutic offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cara Therapeutic's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cara Therapeutic Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cara Therapeutic Stock:

How To Invest In Cara

Details

Is Cara Stock a good investment?

Details

What is Cara Therapeutic's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cara Therapeutic. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For information on how to trade Cara Stock refer to our How to Trade Cara Stock guide.

You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cara Therapeutic. If investors know Cara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cara Therapeutic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(21.00)

Revenue Per Share

1.907

Quarterly Revenue Growth

(0.47)

Return On Assets

(0.62)

Return On Equity

(2.21)

The market value of Cara Therapeutic is measured differently than its book value, which is the value of Cara that is recorded on the company's balance sheet. Investors also form their own opinion of Cara Therapeutic's value that differs from its market value or its book value, called intrinsic value, which is Cara Therapeutic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cara Therapeutic's market value can be influenced by many factors that don't directly affect Cara Therapeutic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Cara Therapeutic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cara Therapeutic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cara Therapeutic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Cara Capital Surpluse vs Net Working Capital Analysis

Capital Surpluse vs Net Working Capital

Capital Surpluse vs Net Working Capital Correlation Analysis

Correlation Coefficient

Capital Surpluse

Net Working Capital

Cara Therapeutic fundamental ratios Correlations

Cara Therapeutic Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Cara Therapeutic fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Cash And Short Term Investments
Property Plant And Equipment Gross	+ 0.99	Property Plant And Equipment Net
Cash And Short Term Investments	+ 0.98	Total Assets
Total Current Assets	+ 0.98	Total Assets
Non Current Liabilities Total	+ 0.97	Short Long Term Debt Total
Common Stock Shares Outstanding	+ 0.97	Common Stock Total Equity

Other Stockholder Equity	- 0.97	Retained Earnings
Net Receivables	- 0.96	Other Assets
Accounts Payable	- 0.94	Retained Earnings
Retained Earnings	- 0.94	Other Current Liab
Net Receivables	- 0.93	Retained Earnings
Retained Earnings	- 0.92	Other Liab